Thomas A. Keuer
Net Worth
Last updated:
What is Thomas A. Keuer net worth?
The estimated net worth of Mr. Thomas A. Keuer is at least $4,074,475 as of 3 Apr 2018. He owns shares worth $32,619 as insider, has earned $15,756 from insider trading and has received compensation worth at least $4,026,100 in ARCA biopharma, Inc..
What is the salary of Thomas A. Keuer?
Mr. Thomas A. Keuer salary is $402,610 per year as Chief Operating Officer in ARCA biopharma, Inc..
How old is Thomas A. Keuer?
Mr. Thomas A. Keuer is 66 years old, born in 1959.
What stocks does Thomas A. Keuer currently own?
As insider, Mr. Thomas A. Keuer owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ARCA biopharma, Inc. (ABIO) | Chief Operating Officer | 13,153 | $2.48 | $32,619 |
What does ARCA biopharma, Inc. do?
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Thomas A. Keuer insider trading
ARCA biopharma, Inc.
Mr. Thomas A. Keuer has made 10 insider trades between 2015-2018, according to the Form 4 filled with the SEC. Most recently he sold 482 units of ABIO stock worth $242 on 3 Apr 2018.
The largest trade he's ever made was exercising 714 units of ABIO stock on 20 Sep 2016. As of 3 Apr 2018 he still owns at least 13,153 units of ABIO stock.
ARCA biopharma key executives
ARCA biopharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Michael R. Bristow M.D., Ph.D. (80) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Christopher D. Ozeroff (66) Senior Vice President, Gen. Counsel & Sec.
- Mr. Thomas A. Keuer (66) Chief Operating Officer